---
document_datetime: 2025-03-18 12:15:21
document_pages: 9
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/riarify-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: riarify-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 4.9422086
conversion_datetime: 2025-12-27 14:08:28.801044
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

| Application number   | Scope                                                                                                      | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on no   | Product Information affected 3   | Summary                           |
|----------------------|------------------------------------------------------------------------------------------------------------|-------------------------------------|------------------------------------------------|----------------------------------|-----------------------------------|
| PSUSA/10617 /202407  | Periodic Safety Update EU Single assessment - beclometasone / formoterol / glycopyrronium bromide product  | 13/02/2025                          | n/a                                            |                                  | PRAC Recommendation - maintenance |
| N/0034               | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification) Medicinal | 04/11/2024                          |                                                | Labelling and PL                 |                                   |

Riarify Procedural steps taken and scientific information after the authorisation number Commission Decision Issued 2  / amended Product Information affected 3 Summary /202407 n/a PRAC Recommendation - maintenance N/0034 Labelling and PL Medicinal product no longer authorised

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

| WS/2659/G   | variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation B.II.a.3.b.2 - Changes in the composition (excipients) of the finished product - Other excipients - Qualitative or quantitative changes in one or more excipients that may have a significant impact on the safety, quality or efficacy of the product B.II.b.5.a - Change to in-process tests or limits applied during the manufacture of the finished   | 19/09/2024   | n/a           | This was an application for a group of product - Tightening of in-process limits   |
|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|---------------|------------------------------------------------------------------------------------|
| /202307     | Periodic Safety Update EU Single assessment - beclometasone / formoterol / glycopyrronium bromide                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 08/02/2024   | n/a no longer | PSUSA/10617                                                                        |
| IG/1701     | B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation product                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 02/02/2024   | n/a           |                                                                                    |
| WS/2604     | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation Medicinal                                                                                                                                                                                                                                                                                 | 25/01/2024   | n/a           |                                                                                    |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| WS/2408   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.III.1.a.3 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - New certificate from a new manufacturer (replacement or addition)                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 14/12/2023    | n/a authorised   |           |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------|------------------|-----------|
| WS/2440/G | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.1.b - Replacement or addition of a manufacturing site for the FP - Primary packaging site B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.b.1.e - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch- release, batch control, primary and secondary packaging, for non-sterile medicinal products product | 04/05/2023 no | n/a longer       | Medicinal |
| IG/1592/G | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 13/02/2023    | n/a              |           |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|                     | A.7 - Administrative change - Deletion of manufacturing sites B.III.2.b - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - Change to comply with an update of the relevant monograph of the Ph. Eur. or national pharmacopoeia of a Member State                  |                       |                                  | authorised                                                                                                                                                                                                                                                            |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|----------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IG/1590             | B.III.2.b - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - Change to comply with an update of the relevant monograph of the Ph. Eur. or national pharmacopoeia of a Member State                                                                                | 09/02/2023            | n/a                              |                                                                                                                                                                                                                                                                       |
| PSUSA/10617 /202207 | Periodic Safety Update EU Single assessment - beclometasone / formoterol / glycopyrronium bromide product                                                                                                                                                                                            | 09/02/2023 n/a no     | longer                           | PRAC Recommendation - maintenance                                                                                                                                                                                                                                     |
| R/0022              | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                              | 13/10/2022 09/12/2022 | SmPC, Annex II, Labelling and PL | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Riarify in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity. |
| IG/1494/G           | This was an application for a group of variations. B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure Medicinal | 18/03/2022            | n/a                              |                                                                                                                                                                                                                                                                       |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|                     | B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure                                                                                                                                                                                                                                                 |            |               |                                              |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|---------------|----------------------------------------------|
| PSUSA/10617 /202107 | Periodic Safety Update EU Single assessment - beclometasone / formoterol / glycopyrronium bromide                                                                                                                                                                                                                                                            | 10/02/2022 | n/a           | PRAC Recommendation - maintenance authorised |
| IG/1478             | B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier                                                                                                                                                                                                                   | 01/02/2022 | n/a           |                                              |
| IG/1469             | A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)                                                                                                                                                             | 03/12/2021 | n/a no longer |                                              |
| N/0017              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                             | 15/11/2021 | 09/12/2022 PL |                                              |
| PSUSA/10617 /202101 | Periodic Safety Update EU Single assessment - beclometasone / formoterol / glycopyrronium bromide product                                                                                                                                                                                                                                                    | 02/09/2021 | n/a           | PRAC Recommendation - maintenance            |
| IG/1422/G           | This was an application for a group of variations. B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the Medicinal | 13/07/2021 | n/a           |                                              |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|         | relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer   |                                     |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|
| WS/2075 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.II.e.1.a.2 - Change in immediate packaging of the finished product - Qualitative and quantitative composition - Semi-solid and non-sterile liquid pharmaceutical forms product                                                                                                                                                    | 08/07/2021 n/a 24/06/2021 no longer |
| WS/2074 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.II.d.1.e - Change in the specification parameters and/or limits of the finished product - Change outside the approved specifications limits range Medicinal                                                                                                                                                                       | n/a                                 |
| IG/1385 | B.II.e.7.a - Change in supplier of packaging components or devices (when mentioned in the dossier) - Deletion of a supplier                                                                                                                                                                                                                                                                                                                                                       | 03/05/2021 n/a                      |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| PSUSA/10617 /202007   | Periodic Safety Update EU Single assessment - beclometasone / formoterol / glycopyrronium bromide                                                                                                                                                                                                                                                                                                              | 11/02/2021    | n/a                        | PRAC Recommendation - maintenance   |
|-----------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------|----------------------------|-------------------------------------|
| IG/1285/G             | This was an application for a group of variations. B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate           | 18/09/2020    | n/a                        | longer authorised                   |
| PSUSA/10617 /202001   | Periodic Safety Update EU Single assessment - beclometasone / formoterol / glycopyrronium bromide                                                                                                                                                                                                                                                                                                              | 04/09/2020 no | n/a                        | PRAC Recommendation - maintenance   |
| IAIN/0008             | A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release product                                                                                                                                                                                                                                                                             | 02/07/2020    | 21/06/2021 Annex II and PL |                                     |
| IG/1226/G             | This was an application for a group of variations. B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate Medicinal | 24/03/2020    | n/a                        |                                     |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|                     | from an already approved manufacturer B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer                                                                                                                                                                                                                                                                                           |                       |             |                                                                                                                         |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|-------------|-------------------------------------------------------------------------------------------------------------------------|
| WS/1734             | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                | 27/02/2020            | n/a         | authorised                                                                                                              |
| PSUSA/10617 /201907 | Periodic Safety Update EU Single assessment - beclometasone / formoterol / glycopyrronium bromide                                                                                                                                                                                                                                                                                                                                                                                                                           | 13/02/2020 no         | n/a longer  | PRAC Recommendation - maintenance                                                                                       |
| PSUSA/10617 /201901 | Periodic Safety Update EU Single assessment - beclometasone / formoterol / glycopyrronium bromide product                                                                                                                                                                                                                                                                                                                                                                                                                   | 11/07/2019 08/04/2019 | n/a         | PRAC Recommendation - maintenance                                                                                       |
| WS/1554             | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Extension of indication, based on results from two Phase III studies: Triple 7 (CCD-05993AA1-07) and Triple 8 (CCD-05993AA1-08), to include maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by combination of a long- acting beta2-agonist and a long-acting muscarinic Medicinal | 28/02/2019            | SmPC and PL | Please refer to the scientific discussion Riarify EMEA/H/C/004836/WS1554/0002 and Trydonis EMEA/H/C/004702/WS1554/0002. |

<div style=\"page-break-after: always\"></div>

<!-- image -->